Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Both FDA and EMA have approved Capecitabine + Trastuzumab + Tucatinib & Breast Cancer / Mammacarcinoma (HER2+) after prior HER2‑directed therapy, but not for early, non‑metastatic disease (1, 4, 5).
In a clinical phase II trial identified as NCT02614794, researchers found that for patients with metastatic Breast cancer / Mammacarcinoma (HER2+)+) who had undergone extensive prior treatments, including those with brain metastases, the combination [Capecitabine + Trastuzumab + Tucati…